Bikam, Dalton Renew, Expand Research Agreement

Bikam and Dalton Medicinal Chemistry (Dalton) have renewed their exclusive worldwide collaboration to discover and develop new ophthalmology therapeutics.

As per the renewed agreement, Dalton will continue to utilise its proprietary insights to advance several novel classes of compounds against selected Bikam targets. Bikam will advance these agents with its growing battery of biological assays and delivery methodologies.

David Garvey, Vice president of Chemistry at Bikam, said: “For the past 18 months we have had a very productive relationship with the Dalton Medicinal Chemistry team.”

Judd Berman, co-founder of Dalton, said: “It’s been exceptionally exciting to work with the talented scientists at B ikam to advance these important programs towards clinical development and beyond. We are delighted to have the opportunity to further contribute to these pioneering programs.”